John R. Moore - Jun 3, 2022 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Role
General Counsel
Signature
/s/ John R. Moore
Stock symbol
EWTX
Transactions as of
Jun 3, 2022
Transactions value $
-$225,644
Form type
4
Date filed
6/7/2022, 07:03 PM
Previous filing
May 18, 2022
Next filing
Jun 10, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EWTX Common Stock Options Exercise $29.4K +15.2K +507.67% $1.93 18.2K Jun 3, 2022 Direct F1, F2
transaction EWTX Common Stock Sale -$92.2K -15.2K -83.54% $6.05 3K Jun 3, 2022 Direct F3
transaction EWTX Common Stock Options Exercise $26.9K +13.9K +464.47% $1.93 16.9K Jun 6, 2022 Direct
transaction EWTX Common Stock Sale -$84.1K -13.9K -82.28% $6.03 3K Jun 6, 2022 Direct F4
transaction EWTX Common Stock Options Exercise $1.88K +973 +32.43% $1.93 3.97K Jun 7, 2022 Direct
transaction EWTX Common Stock Sale -$6.43K -973 -24.49% $6.61 3K Jun 7, 2022 Direct F5
transaction EWTX Common Stock Options Exercise $12.2K +17.2K +571.67% $0.71* 20.2K Jun 7, 2022 Direct
transaction EWTX Common Stock Sale -$113K -17.2K -85.11% $6.61 3K Jun 7, 2022 Direct F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EWTX Stock Option (Right to Buy) Options Exercise $0 -15.2K -6.71% $0.00 212K Jun 3, 2022 Common Stock 15.2K $1.93 Direct F6
transaction EWTX Stock Option (Right to Buy) Options Exercise $0 -13.9K -6.58% $0.00 198K Jun 6, 2022 Common Stock 13.9K $1.93 Direct F6
transaction EWTX Stock Option (Right to Buy) Options Exercise $0 -973 -0.49% $0.00 197K Jun 7, 2022 Common Stock 973 $1.93 Direct F6
transaction EWTX Stock Option (Right to Buy) Options Exercise $0 -17.2K -8.35% $0.00 188K Jun 7, 2022 Common Stock 17.2K $0.71 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on March 16, 2022.
F2 Includes 1,438 shares purchased on May 16, 2022 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
F3 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.12, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.18, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $6.01 to $6.91, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 1/48th of the shares subject to the option vest each month beginning on January 16, 2021, subject to the Reporting Person continuing as a service provider through each vest date.
F7 1/4th of the shares subject to the option became vested and exercisable on September 1, 2021 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date.